Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619]
Toxicol Appl Pharmacol. 2019 Oct 1:380:114701.
doi: 10.1016/j.taap.2019.114701.
Epub 2019 Aug 6.
1 Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
2 Institute of Environmental and Occupational Health Sciences, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
3 Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
4 Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan; Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
5 National Research Institute of Chinese Medicine, Taipei, Taiwan.
6 Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.
7 Division of General Internal Medicine and Geriatrics, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan; Chang Gung University College of Medicine, Taoyuan City, Taiwan.
8 Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic.
9 National Research Institute of Chinese Medicine, Taipei, Taiwan; Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biopharmaceutical Sciences, School of Pharmacy, National Yang-Ming University, Taipei, Taiwan; Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan. Electronic address: ueng@nricm.edu.tw.